Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction in patients without diabetes in Qatar.

Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction in patients without diabetes in Qatar.

<h3>Background</h3><p dir="ltr">Few studies revealed that adding dapagliflozin to standard of care (SoC) among patients with heart failure with reduced ejection fraction (HFrEF) is cost-effective irrespective of diabetes status. However, it remains unclear whether dapagli...

Full description

Saved in:
Bibliographic Details
Main Author: Dina Abushanab (10696501) (author)
Other Authors: Salma Chbib (17269126) (author), Rasha Kaddoura (12506936) (author), Moza Al Hail (2511859) (author), Palli Valappila Abdul Rouf (18472377) (author), Wessam El-Kassem (14829319) (author), Jassim Shah (18015227) (author), Ramesh Nair (9361514) (author), Daoud Al-Badriyeh (832403) (author)
Published: 2024
Subjects:
Biomedical and clinical sciences
Cardiovascular medicine and haematology
Clinical sciences
Pharmacology and pharmaceutical sciences
Economics
Applied economics
Dapagliflozin
Heart failure
Cost-effectiveness
Markov
Qatar
Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items